BMC Cancer

Table 2 Treatment outcome of the full group of 36 nodules

From: Ultrasound-guided implantation of radioactive ¹²⁵I seed in radioiodine refractory differentiated thyroid carcinoma

		Volume (mm³)		Tg (ng/ml)		VRR (%)
Patient no.	Nodule no.	Initial	24 months later	Initial	24 months later	24 months later
1	1^F	11,448	86	>300	147.0	99
2	2	259	0	6.2	4.9	100
	3	919	0	6.2	4.9	100
	4	1507	75	6.2	4.9	95
3	5	528	60	7.9	2.9	89
3	6	528	46	7.9	2.9	93
4	7	308	0	35.2	13.2	100
5	8	251	25	72.4	6.9	90
	9	55	0	72.4	6.9	100
	10	31	0	72.4	6.9	100
	11	141	0	72.4	6.9	100
6	12	299	31	57.0	1.1	90
	13	147	21	57.0	1.1	86
	14	88	0	57.0	1.1	100
7	15	4875	293	114.8	0.7	94
	16	1879	264	114.8	0.7	85
	17	2327	205	114.8	0.7	91
	18	94	0	114.8	0.7	100
8	19	4767	121	1.0	< 0.2	97
9	20	11	0	17.5	< 0.2	100
9	21	15	0	17.5	< 0.2	100
10	22^G	2010	1099	8.6	< 0.2	45
10	23	513	377	8.6	< 0.2	26
11	24	13	0	< 0.2	< 0.2	100
12	25	1717	502	51	20.1	71
13	26^H	19,225	301	119.0	60.4	98
	27	2010	63	119.0	60.4	97
	28	612	91	119.0	60.4	86
	29	518	21	119.0	60.4	96
14	30	1281	403	21.6	6.5	69
15	31	25,017	2213	>300	90.5	91
16	32	314	0	18.2	3.2	100
17	33	452	27	0.8	0.3	94
18	34	5256	1495	>300	>300	72
	35	3843	1143	>300	>300	70
	36^I	151	94	>300	>300	38

^F During the 9th month of follow-up, CEUS indicated partial re-hyper-enhancement of No. 1 nodule, so the secondary implantation was performed
^G US-guided puncture biopsy of No.22 nodule during follow-up indicated that there was no definite metastatic cancer was found
^H During the third month of follow-up, VRR and the serum Tg level reduction of No. 26 nodule were both less than 50%, so the secondary implantation was performed
^I Although VRR reduction of No. 36 nodules were less than 50%, and the serum Tg value > 300 ng/ml, CEUS indicated low to no enhancement of the nodule

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com